From Niagen Bioscience’s (Chromadex) presentation earlier this month at Oppenheimer’s 25th Annual Consumer Growth and E-Commerce Conference:

CEO Rob Fried:

“…In those 40 clinical studies that’ve been published (on Niagen, NR), some of them are very dramatic and significant.

This month, June, this year, we will complete a 4.5 year Phase 3 clinical study on Parkinson’s disease.

That’s 400 participants.

200 receive a placebo.

And 200 receive a gram of Niagen a day for a year.

That’s a very expensive and very extensive (study).

And it’s being conducted by one of the most respected Parkinson’s researchers in the world.

You don’t see that from dietary supplement companies.

You see that from real, hard-core pharma companies and biotech companies.

But we will complete that study this month.

Now, you’re going to say, what are the results?

We don’t know.

It’s a double-blinded, controlled study.

We won’t know the results for months.

And then it will get submitted to some excellent journal and will be peer-reviewed, and probably won’t get published for a year.

So, the public won’t know the results of that study for a year.

But that’s a significant study.

Related:

FOLLOW us on Twitter @RaisingNAD